New hope for ovarian cancer patients resistant to current treatments
NCT ID NCT07340164
First seen Jan 15, 2026 · Last updated May 14, 2026 · Updated 16 times
Summary
This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with ovarian cancer that has come back after treatment with PARP inhibitors. The drug targets a protein called HER2 found on some cancer cells. About 116 adults with HER2-positive ovarian cancer will be randomly assigned to receive either T-DXd or standard chemotherapy. The goal is to see if T-DXd can delay cancer growth better than current options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yonsei University Health System, Severance Hospital
RECRUITINGSeoul, Seoul, 03722, South Korea
Conditions
Explore the condition pages connected to this study.